Observational Study
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Mar 21, 2022; 28(11): 1172-1183
Published online Mar 21, 2022. doi: 10.3748/wjg.v28.i11.1172
Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections
Hsin-Yun Sun, Chien-Yu Cheng, Chi-Ying Lin, Chia-Jui Yang, Nan-Yao Lee, Bo-Huang Liou, Hung-Jen Tang, Yuang-Meng Liu, Chun-Yuan Lee, Tun-Chieh Chen, Yi-Chia Huang, Yuan-Ti Lee, Ming-Jui Tsai, Po-Liang Lu, Hung-Chin Tsai, Ning-Chi Wang, Tung-Che Hung, Shu-Hsing Cheng, Chien-Ching Hung
Hsin-Yun Sun, Chien-Ching Hung, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei 100225, Taiwan
Chien-Yu Cheng, Shu-Hsing Cheng, Department of Infectious Diseases, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan 330215, Taiwan
Chien-Yu Cheng, School of Public Health, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan
Chi-Ying Lin, Ming-Jui Tsai, Department of Internal Medicine, National Taiwan University Hospital Yun-Lin Branch, Yun-Lin County 640203, Taiwan
Chia-Jui Yang, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City 220216, Taiwan
Chia-Jui Yang, Hung-Chin Tsai, School of Medicine, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan
Nan-Yao Lee, Department of Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 704302, Taiwan
Bo-Huang Liou, Department of Internal Medicine, Hsinchu MacKay Memorial Hospital, Hsin-Chu 300044, Taiwan
Hung-Jen Tang, Department of Internal Medicine, Chi Mei Medical Center, Tainan 710402, Taiwan
Hung-Jen Tang, Department of Health and Nutrition, Chia Nan University of Pharmacy and Sciences, Tainan 717301, Taiwan
Yuang-Meng Liu, Department of Internal Medicine, Changhua Christian Hospital, Changhua 500209, Taiwan
Chun-Yuan Lee, Tun-Chieh Chen, Department of Internal Medicine, Kaohsiung Medical University Hospital and College of Medicine, Kaohsiung Medical University, Kaohsiung 807378, Taiwan
Tun-Chieh Chen, Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung 801735, Taiwan
Yi-Chia Huang, Department of Internal Medicine, National Taiwan University Hospital Biomedical Park Branch, Hsin-Chu 302058, Taiwan
Yuan-Ti Lee, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung 402306, Taiwan
Yuan-Ti Lee, School of Medicine, Chung Shan Medical University, Taichung 402306, Taiwan
Po-Liang Lu, Department of Internal Medicine, Kaohsiung Medical University Hospital and College of Medicine, Kaohsiung Medical University, Kaohsiung 807377, Taiwan
Hung-Chin Tsai, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung 813414, Taiwan
Ning-Chi Wang, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 114202, Taiwan
Tung-Che Hung, Department of Internal Medicine, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chia-Yi 600566, Taiwan
Shu-Hsing Cheng, School of Public Health, Taipei Medical University, Taipei 110301, Taiwan
Chien-Ching Hung, Department of Tropical Medicine and Parasitology, National Taiwan University College of Medicine, Taipei 100233, Taiwan
Chien-Ching Hung, Department of Medical Research, China Medical University Hospital, Taichung, 404332, Taiwan
Chien-Ching Hung, China Medical University, Taichung 406040, Taiwan
Author contributions: Sun HY, Cheng CY, and Hung CC managed and supervised the study; Sun HY, Cheng CY, and Hung CC contributed to the study concept and design; Sun HY, Lin CY, Yang CJ, Liou BH, Tang HJ, Tsai MJ, Huang YC, Liu YM, Lee CY, Lu PL, Chen TC, Lee YT, Tsai HC, Wang NC, Cheng SH, Hung TC, Lee L, and Cheng CY were involved in the collection and assembly of clinical data; Sun HY and Hung CC participated in the data analysis; Sun HY, Cheng CY, and Hung CC undertook interpretation of the data and drafted the report; All authors reviewed and approved the final version of the report.
Institutional review board statement: This retrospective study was approved by the Institutional Review Board or Research Ethics Committee of each participating hospital.
Informed consent statement: The requirement for informed consent was waived.
Conflict-of-interest statement: Hung CC has received research support from Janssen, Merck, Gilead Sciences, and ViiV and speaker honoraria from Abbvie, Bristol-Myers Squibb, Gilead Sciences, and ViiV, and served on advisory boards for Gilead Sciences, Janssen, ViiV, and Abbvie. Sun HY has received research support from Gilead Sciences. Other authors have no competing interest to disclose.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Chien-Ching Hung, MD, PhD, Doctor, Full Professor, Staff Physician, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, No. 7 Chung-Shan South Road, Taipei 110, Taiwan. hcc0401@ntu.edu.tw
Received: February 26, 2021
Peer-review started: February 26, 2021
First decision: June 14, 2021
Revised: June 26, 2021
Accepted: January 29, 2022
Article in press: January 29, 2022
Published online: March 21, 2022
Processing time: 383 Days and 18.7 Hours
Core Tip

Core Tip: Similar to the observation made in human immunodeficiency virus-negative patients, virologic response 12 wk off-therapy achieved with direct-acting antivirals (DAAs) was high in human immunodeficiency virus-positive patients coinfected with hepatitis C virus genotype 6. Estimated glomerular filtration rate declined with DAA initiation in patients receiving sofosbuvir and tenofovir disoproxil fumarate or tenofovir alafenamide, which recovered after the completion of DAA treatment.